References in periodicals archive ?
Intro Introduction: A China Biopharmaceuticals Strategy
Paras Biopharmaceuticals Finland Oy has developed innovative manufacturing technologies, namely Diabrid[R], NobleCleav[R] & Biomultifold[R] technologies which enables the economical production of complex biologics & long therapeutic peptides.
- South Korean pharmaceutical company SK Biopharmaceuticals and US-based artificial intelligence -driven biopharmaceutical company twoXAR, Inc have inked an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer (NSCLC), the companies said.
South Korea-based SK Biopharmaceuticals has collaborated with an artificial intelligence-driven biopharmaceutical firm, twoXAR, for the discovery and development of products to treat non-small cell lung cancer, it was reported yesterday.
More than 800,000 people work in the biopharmaceutical industry in the United States across a broad range of occupations, including scientific research, technical support, and manufacturing.
Biopharmaceutical company Arvelle Therapeutics GmbH reported on Wednesday an exclusive licensing agreement to develop and commercialise cenobamate in Europe in partnership with SK Biopharmaceuticals.
T601 and T101 are now being developed by Tasly Biopharmaceuticals for patients in Greater China2.
Along with cost factors, the report lists regulations, high-end product development/ manufacturing requirements and cold storage requirements as challenges and restraints, but make no mistake, the arrow for biopharmaceuticals points up.
The report " Downstream Bioprocessing Market and Downstream Processing in Biopharmaceuticals by Technique (Separation, Concentration, Purification), Product (Chromatography Column & Resin, Filter, Single use), Application (Mab Production), End User (Contract Manufacturing Organization) - Global Forecast to 2021, The Downstream Bioprocessing Market and Downstream Processing in Biopharmaceuticals is poised to reach USD 22.03 Billion by 2021 from USD 10.32 Billion in 2016, at a CAGR of 16.4% from 2016 to 2021..
For the further analysis of the evolution and policy transition of biopharmaceuticals in China, this article is structured as the following.